On Thursday, US pharmaceutical firm Eli Lilly has presented convincing data in favor of the drug candidate tirzepatide, which is a GLP-1 analog.
In the Surpass II study the US company compared high doses of the drug with Novo Nordisk's approved 1mg semaglutide dose.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.